Clinical Trial

Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia

Study acronym: RCT
Completed Phase 4
View on ClinicalTrials.gov →
Summary
Article: Clinical Outcomes of Inhaled Amikacin in Ventilator-Associated Pneumonia: A group randomized controlled,add-on trial English:Patients in intensive care units often need ventilators to breathe. Sadly, these machines sometimes cause serious lung infections, known as ventilator-associated pneumonia (VAP). This study tested whether giving the antibiotic amikacin by inhalation (so itgoes straight into the lungs) could improve recovery when added to regular treatment. Researchers looked at how quickly infections cleared, how long patients needed the ventilator, and whether hospital stays were shortened. They also monitored for side effects.
Trial Details
NCT Number NCT07369336
Lead Sponsor Postgraduate Medical Institute, Lahore
Conditions Ventilator Associated Pneumonia ( VAP)
Enrollment 90 participants
Start Date 2024-01-05
Primary Completion 2024-11-25 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-27